BAYZED HEALTH

Bayzed Health surged 5.23% to HKD 3.02 in the morning session, driven by a disclosed RMB188 million loans and guarantees to a partner hospital, combined with Q4 net profit jumping 902.88% YoY and operating income rising 25.83%. The stock opened at HKD 2.81, then climbed steadily to the intraday high of HKD 3.02, closing at the session peak. However, the price remains 84.81% below the 52-week high of HKD 19.88 and down 22.37% YTD, trading above the MA20 (HKD 2.909) but below the MA60 (HKD 4.318), indicating near-term strength against lingering long-term resistance.

Bayzed Health (2609.HK) opened the morning session with a 5.46% surge to HK$3.09, driven by the announcement of Tsang Chun Ho as joint company secretary and authorized representative, coupled with a technical rebound after sustained weakness. The entire session saw only one trade of 30,600 shares reaching the day's high, indicating concentrated buying but thin liquidity. Q4 2025 net profit surged 902.88% YoY to HK$8.15 million despite revenue declining 7.78% YoY, with net margin at just 2.69%, suggesting earnings improvement came from cost control rather than top-line growth. The stock trades 84.46% below its 52-week high of HK$19.88, down 20.57% YTD, and remains below its MA20 (HK$3.14) and MA60 (HK$4.496), with a PB of 2.42x placing it at the lower end of its historical range. However, earlier selling by GREEN ECONOMY for HK$18.4 million signals continued pressure from early shareholders.

Bayzed Health Group rebounded from an intraday low of HK$2.94 to a high of HK$3.11 in the morning session, closing up 5.42% at HK$3.11 on volume of about 1.29 million shares and turnover of HK$3.91 million. The rally was driven by its latest earnings improvement: Q4 2025 net profit surged 903% YoY to HK$8.15 million, EPS jumped 898% YoY to HK$0.0068, and operating income rose 25.8% YoY to HK$14.52 million, although revenue fell 7.78% YoY to HK$303 million, indicating profit gains were cost-led rather than revenue-driven. The stock remains 84.36% below its 52-week high of HK$19.88, trades below both its 20-day (HK$3.367) and 60-day (HK$4.574) moving averages, and is down 20.05% YTD. Valuation is stretched with a P/E of -285.84x, though P/B is 2.44x. However, recent news of management changes and loan guarantees to a partner hospital has kept volatility elevated.

Bayzed Health opened lower and rallied in the morning session, last trading at HK$2.96 as of 09:36 BJ, up 5.34% from prior close of HK$2.81, with an intraday range of HK$2.82 to HK$2.94, likely driven by today's announcement of a joint company secretary appointment. The stock has a trailing P/E of -272x and P/B of 2.32x, with a market cap of approximately HK$3.9 billion. While Q4 2025 operating revenue fell 7.78% YoY to HK$303 million, net profit surged 902.88% YoY to HK$8.15 million, and EPS rose to HK$0.0068. However, the price remains weak, down 23.91% YTD and 85.11% from its 52-week high of HK$19.88, and at HK$2.96 it trades below both the 20-day MA (HK$3.469) and 60-day MA (HK$4.605).

Bai Ze Medical Group staged a low-open rally in the morning session, closing at HK$3.13 as of 11:00 BJ, up 5.74% from the previous close of HK$2.96, driven mainly by a technical rebound after two consecutive days of sharp declines. The stock hit an intraday high of HK$3.13, while the low of HK$2.94 occurred just one minute after the open. The current price is 84.31% below the 52-week high of HK$19.88, but still 17.74% above the 52-week low of HK$2.65, and well below both the 20-day MA (HK$4.5) and 60-day MA (HK$4.944), reflecting ongoing valuation pressure. In Q4 2025, net profit surged 902.88% YoY to approximately HK$8.15 million, with EPS of HK$0.0068, but revenue fell 7.78% YoY and net profit margin was only 2.69%, indicating fragile earnings quality. However, the stock had plunged over 14% and 8% on June 8 and June 9 respectively, and today's rebound was modest, with turnover of only about HK$7.37 million, suggesting thin participation.